Aurinia Pharmaceuticals Inc (AUPH) Announces Earnings Results, Misses Estimates By $0.02 EPS
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) announced its earnings results on Tuesday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.02), Briefing.com reports. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. The company’s revenue was up .0% on a year-over-year basis.
Aurinia Pharmaceuticals (NASDAQ:AUPH) traded down $0.15 during trading hours on Tuesday, hitting $5.62. 729,100 shares of the stock traded hands, compared to its average volume of 3,840,873. Aurinia Pharmaceuticals has a one year low of $2.02 and a one year high of $10.54.
A number of equities analysts recently issued reports on the stock. Vetr lowered shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating and set a $6.64 target price for the company. in a research report on Wednesday, September 6th. Seaport Global Securities reiterated a “buy” rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, October 6th. BidaskClub lowered shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Tuesday, August 15th. Finally, Leerink Swann increased their target price on shares of Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the company an “outperform” rating in a research report on Monday, October 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $10.79.
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.